Pliant Therapeutics, Inc. (PLRX)
PLRX Stock Price Chart
Explore Pliant Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PLRX price movements and trends.
PLRX Company Profile
Discover essential business fundamentals and corporate details for Pliant Therapeutics, Inc. (PLRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Jun 2020
Employees
171.00
Website
https://pliantrx.comCEO
Bernard Coulie
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
PLRX Financial Timeline
Browse a chronological timeline of Pliant Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.52.
Earnings released on 7 Aug 2025
EPS came in at -$0.71 falling short of the estimated -$0.62 by -14.52%.
Earnings released on 8 May 2025
EPS came in at -$0.92 falling short of the estimated -$0.78 by -17.95%.
Earnings released on 3 Mar 2025
EPS came in at -$0.82 surpassing the estimated -$0.99 by +17.17%.
Earnings released on 7 Nov 2024
EPS came in at -$0.95 surpassing the estimated -$0.99 by +4.04%.
Earnings released on 7 Aug 2024
EPS came in at -$0.92 falling short of the estimated -$0.85 by -8.24%.
Earnings released on 6 May 2024
EPS came in at -$0.78 falling short of the estimated -$0.76 by -2.63%.
Earnings released on 27 Feb 2024
EPS came in at -$0.69 surpassing the estimated -$0.81 by +14.81%, while revenue for the quarter reached $4.84M , beating expectations by +494.51%.
Earnings released on 9 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.78 by +10.26%.
Earnings released on 9 Aug 2023
EPS came in at -$0.70 surpassing the estimated -$0.73 by +4.11%, while revenue for the quarter reached $248.00K , missing expectations by -71.82%.
Earnings released on 9 May 2023
EPS came in at -$0.67 falling short of the estimated -$0.66 by -1.52%, while revenue for the quarter reached $1.33M , beating expectations by +10.08%.
Earnings released on 9 Mar 2023
EPS came in at -$0.72 falling short of the estimated -$0.70 by -2.86%, while revenue for the quarter reached $1.97M , beating expectations by +35.46%.
Earnings released on 8 Nov 2022
EPS came in at -$0.65 surpassing the estimated -$0.74 by +12.16%, while revenue for the quarter reached $1.48M , missing expectations by -17.32%.
Earnings released on 8 Aug 2022
EPS came in at -$0.82 matching the estimated -$0.82, while revenue for the quarter reached $4.99M , beating expectations by +269.59%.
Earnings released on 9 May 2022
EPS came in at -$0.78 falling short of the estimated -$0.77 by -1.30%, while revenue for the quarter reached $1.25M , missing expectations by -0.87%.
Earnings released on 28 Feb 2022
EPS came in at -$0.68 surpassing the estimated -$0.76 by +10.53%, while revenue for the quarter reached $2.00M , missing expectations by -33.37%.
Earnings released on 9 Nov 2021
EPS came in at -$0.75 falling short of the estimated -$0.71 by -5.63%, while revenue for the quarter reached $1.61M , missing expectations by -8.00%.
Earnings released on 9 Aug 2021
EPS came in at -$0.64 matching the estimated -$0.64, while revenue for the quarter reached $1.79M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$0.64 falling short of the estimated -$0.59 by -8.47%, while revenue for the quarter reached $2.17M , beating expectations by +7.14%.
Earnings released on 16 Mar 2021
EPS came in at -$0.54 surpassing the estimated -$0.71 by +23.94%, while revenue for the quarter reached $4.47M .
Earnings released on 10 Nov 2020
EPS came in at -$0.47 surpassing the estimated -$1.10 by +57.27%, while revenue for the quarter reached $4.81M .
PLRX Stock Performance
Access detailed PLRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.